Advertisement
Review Article| Volume 56, ISSUE 1, P157-168, February 2023

Unified Airway Disease

Medical Management
Published:October 17, 2022DOI:https://doi.org/10.1016/j.otc.2022.09.012

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Otolaryngologic Clinics of North America
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ryu G.
        • Min C.
        • Park B.
        • et al.
        Bidirectional association between asthma and chronic rhinosinusitis: Two longitudinal follow-up studies using a national sample cohort.
        Sci Rep. 2020; 10: 1-10
        • Jarvis D.
        • Newson R.
        • Lotvall J.
        • et al.
        Asthma in adults and its association with chronic rhinosinusitis: the GA2LEN survey in Europe.
        Allergy. 2012; 67: 91-98
        • Novelli F.
        • Bacci E.
        • Latorre M.
        • et al.
        Comorbidities are associated with different features of severe asthma.
        Clin Mol Allergy. 2018; 16https://doi.org/10.1186/S12948-018-0103-X
        • Bilodeau L.
        • Boulay M.È.
        • Prince P.
        • et al.
        Comparative clinical and airway inflammatory features of asthmatics with or without polyps.
        Rhinology. 2010; 48: 420-425
        • Obaseki D.
        • Potts J.
        • Joos G.
        • et al.
        The relation of airway obstruction to asthma, chronic rhinosinusitis and age: results from a population survey of adults.
        Allergy. 2014; 69: 1205
        • Van Zele T.
        • Claeys S.
        • Gevaert P.
        • et al.
        Differentiation of chronic sinus diseases by measurement of inflammatory mediators.
        Allergy. 2006; 61: 1280-1289
        • Bachert C.
        • Marple B.
        • Hosemann W.
        • et al.
        Endotypes of chronic rhinosinusitis with nasal polyps: pathology and possible therapeutic implications.
        J Allergy Clin Immunol Pract. 2020; 8: 1514-1519
        • Zhang N.
        • Van Zele T.
        • Perez-Novo C.
        • et al.
        Different types of T-effector cells orchestrate mucosal inflammation in chronic sinus disease.
        J Allergy Clin Immunol. 2008; 122: 961-968
        • Liu Y.
        • Zeng M.
        • Liu Z.
        Th17 response and its regulation in inflammatory upper airway diseases.
        Clin Exp Allergy. 2015; 45: 602-612
        • Ghogomu N.
        • Kern R.
        Chronic rhinosinusitis: the rationale for current treatments.
        Expert Rev Clin Immunol. 2017; 13: 259-270
        • Stevens W.W.
        • Peters A.T.
        • Tan B.K.
        • et al.
        Associations between inflammatory endotypes and clinical presentations in chronic rhinosinusitis.
        J Allergy Clin Immunol Pract. 2019; 7: 2812-2820.e3
        • Tomassen P.
        • Vandeplas G.
        • Van Zele T.
        • et al.
        Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers.
        J Allergy Clin Immunol. 2016; 137: 1449-1456.e4
        • Delemarre T.
        • Holtappels G.
        • De Ruyck N.
        • et al.
        Type 2 inflammation in chronic rhinosinusitis without nasal polyps: Another relevant endotype.
        J Allergy Clin Immunol. 2020; 146: 337-343.e6
      1. Fokkens W.J., Lund V.J., Hopkins C., et al., European Position Paper on Rhinosinusitis and Nasal Polyps 2020, Rhinology, 58 (Suppl S29), 2020, 1-464.

        • Avdeeva K.
        • Fokkens W.
        Precision medicine in chronic rhinosinusitis with nasal polyps.
        Curr Allergy Asthma Rep. 2018; 18https://doi.org/10.1007/S11882-018-0776-8
        • Hopkins C.
        Chronic rhinosinusitis with nasal polyps.
        N Engl J Med. 2019; 381: 55-63
        • Chong L.Y.
        • Head K.
        • Hopkins C.
        • et al.
        Saline irrigation for chronic rhinosinusitis.
        Cochrane Database Syst Rev. 2016; 2016https://doi.org/10.1002/14651858.CD011995.pub2
        • Chong L.Y.
        • Head K.
        • Hopkins C.
        • et al.
        Different types of intranasal steroids for chronic rhinosinusitis.
        Cochrane Database Syst Rev. 2016; 2016https://doi.org/10.1002/14651858.CD011993.pub2
        • Chong L.Y.
        • Head K.
        • Hopkins C.
        • et al.
        Intranasal steroids versus placebo or no intervention for chronic rhinosinusitis.
        Cochrane Database Syst Rev. 2016; 2016https://doi.org/10.1002/14651858.CD011996.pub2
        • Rudmik L.
        • Xu Y.
        • Liu M.
        • et al.
        Utilization patterns of topical intranasal steroid therapy for chronic rhinosinusitis: a canadian population-based analysis.
        JAMA Otolaryngol Head Neck Surg. 2016; 142: 1056-1062
        • Dixon A.E.
        • Castro M.
        • Cohen R.I.
        • et al.
        Efficacy of nasal mometasone for the treatment of chronic sinonasal disease in patients with inadequately controlled asthma.
        J Allergy Clin Immunol. 2015; 135: 701-709.e5
        • Jiramongkolchai P.
        • Patel S.
        • Schneider J.S.
        Use of off-label nasal steroid irrigations in long-term management of chronic rhinosinusitis.
        Ear Nose Throat J. 2021; 100: 329-334
        • Harvey R.J.
        • Snidvongs K.
        • Kalish L.H.
        • et al.
        Corticosteroid nasal irrigations are more effective than simple sprays in a randomized double-blinded placebo-controlled trial for chronic rhinosinusitis after sinus surgery.
        Int Forum Allergy Rhinol. 2018; 8: 461-470
        • Kalish L.
        • Snidvongs K.
        • Sivasubramaniam R.
        • et al.
        Topical steroids for nasal polyps.
        Cochrane Database Syst Rev. 2012; 12: CD006549
        • Tait S.
        • Kallogjeri D.
        • Suko J.
        • et al.
        Effect of budesonide added to large-volume, low-pressure saline sinus irrigation for chronic rhinosinusitis: a randomized clinical trial.
        JAMA Otolaryngol Head Neck Surg. 2018; 144: 605
        • Brown H.J.
        • Batra P.S.
        • Eggerstedt M.
        • et al.
        The possibility of short-term hypothalamic-pituitary-adrenal axis suppression with high-volume, high-dose nasal mometasone irrigation in postsurgical patients with chronic rhinosinusitis.
        Int Forum Allergy Rhinol. 2022; 12: 249-256
        • Smith K.A.
        • French G.
        • Mechor B.
        • et al.
        Safety of long-term high-volume sinonasal budesonide irrigations for chronic rhinosinusitis.
        Int Forum Allergy Rhinol. 2016; 6: 228-232
        • Sindwani R.
        • Han J.K.
        • Soteres D.F.
        • et al.
        NAVIGATE I: randomized, placebo-controlled, double-blind trial of the exhalation delivery system with fluticasone for chronic rhinosinusitis with nasal polyps.
        Am J Rhinol Allergy. 2019; 33: 69-82
        • Leopold D.A.
        • Elkayam D.
        • Messina J.C.
        • et al.
        NAVIGATE II: Randomized, double-blind trial of the exhalation delivery system with fluticasone for nasal polyposis.
        J Allergy Clin Immunol. 2019; 143: 126-134.e5
        • Goshtasbi K.
        • Abouzari M.
        • Abiri A.
        • et al.
        Efficacy of steroid eluting stents in management of chronic rhinosinusitis following endoscopic sinus surgery: updated meta-analysis.
        Int Forum Allergy Rhinol. 2019; 9: 1443
        • Kern R.C.
        • Stolovitzky J.P.
        • Silvers S.L.
        • et al.
        A phase 3 trial of mometasone furoate sinus implants for chronic sinusitis with recurrent nasal polyps.
        Int Forum Allergy Rhinol. 2018; 8: 471-481
        • Forwith K.D.
        • Han J.K.
        • Stolovitzky J.P.
        • et al.
        RESOLVE: bioabsorbable steroid-eluting sinus implants for in-office treatment of recurrent sinonasal polyposis after sinus surgery: 6-month outcomes from a randomized, controlled, blinded study.
        Int Forum Allergy Rhinol. 2016; 6: 573-581
        • Han J.K.
        • Forwith K.D.
        • Smith T.L.
        • et al.
        RESOLVE: a randomized, controlled, blinded study of bioabsorbable steroid-eluting sinus implants for in-office treatment of recurrent sinonasal polyposis.
        Int Forum Allergy Rhinol. 2014; 4: 861-870
        • Han J.K.
        • Kern R.C.
        Topical therapies for management of chronic rhinosinusitis: steroid implants.
        Int Forum Allergy Rhinol. 2019; 9: S22-S26
        • Douglas R.G.
        • Psaltis A.J.
        • Rimmer J.
        • et al.
        Phase 1 clinical study to assess the safety of a novel drug delivery system providing long-term topical steroid therapy for chronic rhinosinusitis.
        Int Forum Allergy Rhinol. 2019; 9: 378-387
        • Wen W.
        • Liu W.
        • Zhang L.
        • et al.
        Increased neutrophilia in nasal polyps reduces the response to oral corticosteroid therapy.
        J Allergy Clin Immunol. 2012; 129: 1522-1528.e5
        • Head K.
        • Chong L.Y.
        • Hopkins C.
        • et al.
        Short-course oral steroids as an adjunct therapy for chronic rhinosinusitis.
        Cochrane Database Syst Rev. 2016; 2016https://doi.org/10.1002/14651858.CD011992.pub2
        • Sullivan P.W.
        • Ghushchyan V.H.
        • Globe G.
        • et al.
        Oral corticosteroid exposure and adverse effects in asthmatic patients.
        J Allergy Clin Immunol. 2018; 141: 110-116.e7
        • Matsumoto H.
        • Ishihara K.
        • Hasegawa T.
        • et al.
        Effects of inhaled corticosteroid and short courses of oral corticosteroids on bone mineral density in asthmatic patients : a 4-year longitudinal study.
        Chest. 2001; 120: 1468-1473
        • Stuck A.E.
        • Minder C.E.
        • Frey F.J.
        Risk of infectious complications in patients taking glucocorticosteroids.
        Rev Infect Dis. 1989; 11: 954-963
        • Leung R.M.
        • Smith T.L.
        • Kern R.C.
        • et al.
        Should oral corticosteroids be used in medical therapy for chronic rhinosinusitis? A risk analysis.
        Laryngoscope. 2021; 131: 473-481
        • Lal D.
        • Scianna J.M.
        • Stankiewicz J.A.
        Efficacy of targeted medical therapy in chronic rhinosinusitis, and predictors of failure.
        Am J Rhinol Allergy. 2009; 23: 396-400
        • Baguley C.
        • Brownlow A.
        • Yeung K.
        • et al.
        The fate of chronic rhinosinusitis sufferers after maximal medical therapy.
        Int Forum Allergy Rhinol. 2014; 4: 525-532
        • Ramakrishnan V.R.
        • Feazel L.M.
        • Abrass L.J.
        • et al.
        Prevalence and abundance of Staphylococcus aureus in the middle meatus of patients with chronic rhinosinusitis, nasal polyps, and asthma.
        Int Forum Allergy Rhinol. 2013; 3: 267-271
        • Kim Y.C.
        • Won H.K.
        • Lee J.W.
        • et al.
        Staphylococcus aureus nasal colonization and asthma in adults: systematic review and meta-analysis.
        J Allergy Clin Immunol Pract. 2019; 7: 606-615.e9
        • Pinto Bezerra Soter A.C.
        • Pinto Bezerra T.F.
        • Pezato R.
        • et al.
        Prospective open-label evaluation of long-term low-dose doxycycline for difficult-to-treat chronic rhinosinusitis with nasal polyps.
        Rhinology. 2017; 55: 175-180
        • Van Zele T.
        • Gevaert P.
        • Holtappels G.
        • et al.
        Oral steroids and doxycycline: two different approaches to treat nasal polyps.
        J Allergy Clin Immunol. 2010; 125https://doi.org/10.1016/J.JACI.2010.02.020
        • Varvyanskaya A.
        • Lopatin A.
        Efficacy of long-term low-dose macrolide therapy in preventing early recurrence of nasal polyps after endoscopic sinus surgery.
        Int Forum Allergy Rhinol. 2014; 4: 533-541
        • Wallwork B.
        • Coman W.
        • Mackay-Sim A.
        • et al.
        A double-blind, randomized, placebo-controlled trial of macrolide in the treatment of chronic rhinosinusitis.
        Laryngoscope. 2006; 116: 189-193
      2. Workstream 2: The MACRO Programme | Workstream 2: The MACRO Programme.
        (Available at:) (Accessed May 8, 2022)
        • Lourijsen E.S.
        • Reitsma S.
        • Vleming M.
        • et al.
        Endoscopic sinus surgery with medical therapy versus medical therapy for chronic rhinosinusitis with nasal polyps: a multicentre, randomised, controlled trial.
        Lancet Respir Med. 2022; 10: 337-346
        • Laidlaw T.M.
        • Mullol J.
        • Woessner K.M.
        • et al.
        Chronic rhinosinusitis with nasal polyps and asthma.
        J Allergy Clin Immunol Pract. 2021; 9: 1133-1141
      3. Nucala | european medicines agency.
        (Available at:) (Accessed May 1, 2022)
      4. Dupixent | european medicines agency.
        (Available at:) (Accessed May 1, 2022)
      5. Xolair | european medicines agency.
        (Available at:) (Accessed May 1, 2022)
        • Hopkins C.
        • Wagenmann M.
        • Bachert C.
        • et al.
        Efficacy of dupilumab in patients with a history of prior sinus surgery for chronic rhinosinusitis with nasal polyps.
        Int Forum Allergy Rhinol. 2021; 11: 1087-1101
        • Bajpai S.
        • Marino M.J.
        • Rank M.A.
        • et al.
        Benefits of biologic therapy administered for asthma on co-existent chronic rhinosinusitis: a real-world study.
        Int Forum Allergy Rhinol. 2021; 11: 1152-1161
        • Chong L.Y.
        • Piromchai P.
        • Sharp S.
        • et al.
        Biologics for chronic rhinosinusitis.
        Cochrane Database Syst Rev. 2021; 2021https://doi.org/10.1002/14651858.CD013513.PUB3
        • Hopkins C.
        • Buchheit K.
        • Heffler E.
        • et al.
        Dupilumab improved health-related quality of life in asthma patients with comorbid chronic rhinosinusitis: QUEST study.
        Am Thorac Soc Int. 2022; : A4845https://doi.org/10.1164/AJRCCM-CONFERENCE.2022.205.1_MEETINGABSTRACTS.A4845
        • Buchheit K.M.
        • Sohail A.
        • Hacker J.
        • et al.
        Rapid and sustained effect of dupilumab on clinical and mechanistic outcomes in aspirin-exacerbated respiratory disease.
        J Allergy Clin Immunol. 2022; https://doi.org/10.1016/j.jaci.2022.04.007
        • Lans van der R.J.L.
        • Fokkens W.J.
        • Adriaensen G.F.J.P.M.
        • et al.
        Real-life observational cohort verifies high efficacy of dupilumab for chronic rhinosinusitis with nasal polyps.
        Allergy. 2022; 77: 670-674
        • Han J.K.
        • Bachert C.
        • Fokkens W.
        • et al.
        Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial.
        Lancet Respir Med. 2021; 9: 1141-1153https://doi.org/10.1016/S2213-2600(21)00097-7
        • Weinstein S.F.
        • Katial R.K.
        • Bardin P.
        • et al.
        Effects of reslizumab on asthma outcomes in a subgroup of eosinophilic asthma patients with self-reported chronic rhinosinusitis with nasal polyps.
        J Allergy Clin Immunol Pract. 2019; 7: 589-596.e3
        • Hayashi H.
        • Mitsui C.
        • Fukutomi Y.
        • et al.
        Efficacy of reslizumab with asthma, chronic sinusitis with nasal polyps and elevated blood eosinophils.
        J Allergy Clin Immunol. 2016; 137: AB86
        • Bachert C.
        • Han J.K.
        • Desrosiers M.Y.
        • et al.
        Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo-controlled trial.
        J Allergy Clin Immunol. 2022; 149: 1309-1317.e12
        • Gevaert P.
        • Omachi T.A.
        • Corren J.
        • et al.
        Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials.
        J Allergy Clin Immunol. 2020; 146: 595-605
        • Bachert C.
        • Han J.K.
        • Wagenmann M.
        • et al.
        EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: Definitions and management.
        J Allergy Clin Immunol. 2021; 147: 29-36
        • Wu Q.
        • Zhang Y.
        • Kong W.
        • et al.
        Which is the best biologic for nasal polyps: dupilumab, omalizumab, or mepolizumab? A network meta-analysis.
        Int Arch Allergy Immunol. 2022; 183: 279-288
        • Walter S.
        • Ho J.
        • Alvarado R.
        • et al.
        Mepolizumab decreases tissue eosinophils while increasing type-2 cytokines in eosinophilic chronic rhinosinusitis.
        Clin Exp Allergy. 2022; https://doi.org/10.1111/cea.14152
        • van der Lans R.J.L.
        • Hopkins C.
        • Senior B.A.
        • et al.
        Biologicals and endoscopic sinus surgery for severe uncontrolled chronic rhinosinusitis with nasal polyps: an economic perspective.
        J Allergy Clin Immunol Pract. 2022; https://doi.org/10.1016/j.jaip.2022.02.017
        • Bachert C.
        • Han J.K.
        • Desrosiers M.
        • et al.
        Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
        Lancet (London, England). 2019; 394: 1638-1650
        • Scangas G.A.
        • Wu A.W.
        • Ting J.Y.
        • et al.
        Cost utility analysis of dupilumab versus endoscopic sinus surgery for chronic rhinosinusitis with nasal polyps.
        Laryngoscope. 2021; 131: E26-E33
        • Yong M.
        • Wu Y.Q.
        • Howlett J.
        • et al.
        Cost-effectiveness analysis comparing dupilumab and aspirin desensitization therapy for chronic rhinosinusitis with nasal polyposis in aspirin-exacerbated respiratory disease.
        Int Forum Allergy Rhinol. 2021; 11: 1626-1636